Endotronix is a technology company.
Endotronix has raised $70.0M across 1 funding round.
Endotronix has raised $70.0M in total across 1 funding round.
Endotronix has raised $70.0M in total across 1 funding round.
Endotronix's investors include EQT Life Sciences, Founder Collective, Stanley Ventures, SVG Ventures-THRIVE.
Endotronix is a digital health medtech company specializing in advanced heart failure management through innovative wireless monitoring technology. Its flagship product, the Cordella™ Heart Failure System, integrates an implantable pulmonary artery (PA) pressure sensor with a cloud-based disease management platform to enable remote, proactive monitoring of congestive heart failure (CHF) patients. This system serves patients with NYHA Class III heart failure, clinicians, and caregivers by providing continuous, real-time data that helps reduce hospitalizations, optimize medication, and improve quality of life. Endotronix has demonstrated strong growth momentum, including FDA approval of the Cordella PA Sensor and over 500 implants worldwide, culminating in its acquisition by Edwards Lifesciences in 2024[1][2][4][5][6][7].
Founded in 2007 by Harry Rowland, PhD, and Anthony Nunez, MD, Endotronix emerged from a vision to improve heart failure care through pulmonary artery sensing technology. Early milestones included the first-in-human implant of the Cordella PA Sensor during the SIRONA trial and subsequent pivotal trials like PROACTIVE-HF, which provided critical clinical validation. These achievements helped establish Endotronix as a leader in hemodynamic monitoring and digital health for cardiovascular disease[1][5].
Endotronix rides the growing trend toward remote patient monitoring and data-driven, proactive healthcare management, particularly in chronic disease management. The timing is critical as healthcare systems increasingly emphasize reducing hospital readmissions and costs while improving patient outcomes. Advances in implantable sensors, cloud computing, and telehealth converge in Endotronix’s solution, positioning it at the forefront of digital transformation in cardiovascular care. By enabling continuous hemodynamic monitoring outside the hospital, Endotronix influences the broader ecosystem by setting new standards for heart failure management and encouraging integration of medical devices with digital health platforms[6][8].
Looking ahead, Endotronix is poised to expand its market presence following FDA approval and acquisition by Edwards Lifesciences, with plans to pursue CE Mark approval for Europe. The company’s trajectory will be shaped by trends in personalized medicine, remote monitoring, and value-based care models. As healthcare providers increasingly adopt data-driven tools, Endotronix’s influence is likely to grow, potentially extending its platform to other cardiovascular conditions and integrating with broader digital health ecosystems. This evolution underscores Endotronix’s role as a pioneer in transforming heart failure care from reactive to proactive management, fulfilling its mission to improve patient outcomes through innovative technology[5][6].
Endotronix has raised $70.0M across 1 funding round. Most recently, it raised $70.0M Series D in September 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2018 | $70.0M Series D | EQT Life Sciences, Founder Collective, Stanley Ventures, SVG Ventures-THRIVE |